Drugs in R & D

, Volume 3, Issue 3, pp 210–211 | Cite as

NC 100100

DD 723, NUS, Sonazoid
Adis R&D Profile


Myocardial Perfusion Imaging Ultrasound Contrast Agent Cardiac Perfusion European Medicine Evaluation Agency Acute Coronary Occlusion 


  1. 1.
    Towart R, Karlsson JOG, Moen O, et al. NC100100 has no negative effects on experimental infarct size in dogs. Naunyn- Schmiedeberg’s Arch Pharmacol 358 (Suppl 2): 616 (Poster), No. 1, 1998Google Scholar
  2. 2.
    Yao JF, Teupe C, Takeuchi M, et al. Quantitative 3-dimensional contrast echocardiographic determination ofmyocardial mass at risk and residual infarct mass after reperfusion: experimental canine studies with intravenous contrast agent NC100100. J Am Soc Echocardiogr 13: 570–581, Jun 2000PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations